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Increasing the CpG dinucleotide 
abundance in the HIV‑1 genomic RNA inhibits 
viral replication
Irati Antzin‑Anduetza, Charlotte Mahiet, Luke A. Granger, Charlotte Odendall and Chad M. Swanson* 
Abstract 
Background: The human immunodeficiency virus type 1 (HIV‑1) structural protein Gag is necessary and sufficient 
to form viral particles. In addition to encoding the amino acid sequence for Gag, the underlying RNA sequence could 
encode cis‑acting elements or nucleotide biases that are necessary for viral replication. Furthermore, RNA sequences 
that inhibit viral replication could be suppressed in gag. However, the functional relevance of RNA elements and 
nucleotide biases that promote or repress HIV‑1 replication remain poorly understood.
Results: To characterize if the RNA sequence in gag controls HIV‑1 replication, the matrix (MA) region was codon 
modified, allowing the RNA sequence to be altered without affecting the protein sequence. Codon modification of 
nucleotides (nt) 22‑261 or 22‑378 in gag inhibited viral replication by decreasing genomic RNA (gRNA) abundance, 
gRNA stability, Gag expression, virion production and infectivity. Comparing the effect of these point mutations to 
deletions of the same region revealed that the mutations inhibited infectious virus production while the deletions 
did not. This demonstrated that codon modification introduced inhibitory sequences. There is a much lower than 
expected frequency of CpG dinucleotides in HIV‑1 and codon modification introduced a substantial increase in CpG 
abundance. To determine if they are necessary for inhibition of HIV‑1 replication, codons introducing CpG dinucleo‑
tides were mutated back to the wild type codon, which restored efficient Gag expression and infectious virion pro‑
duction. To determine if they are sufficient to inhibit viral replication, CpG dinucleotides were inserted into gag in the 
absence of other changes. The increased CpG dinucleotide content decreased HIV‑1 infectivity and viral replication.
Conclusions: The HIV‑1 RNA sequence contains low abundance of CpG dinucleotides. Increasing the abundance of 
CpG dinucleotides inhibits multiple steps of the viral life cycle, providing a functional explanation for why CpG dinu‑
cleotides are suppressed in HIV‑1.
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© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The HIV-1 genomic RNA (gRNA) has three major func-
tions in the viral life cycle [1]. First, it serves as the pre-
mRNA that is spliced into over 70 different transcripts 
[2–4]. Second, it acts as the mRNA for the Gag and Gag-
Pol polyproteins that comprise the structural and enzy-
matic proteins, respectively [5, 6]. Third, it is the genome 
that is packaged into virions and is reverse-transcribed 
upon infection of a new target cell [7, 8]. The gRNA can 
be divided into three regions: a 336 nt 5′ untranslated 
region (UTR), a 219 nt 3′ UTR, and an 8618 nt region 
that is densely packed with multiple open reading frames 
(nt lengths reference the HIV-1NL4-3 strain [9]). The 5′ 
UTR contains several cis-acting elements in complex 
stem-loop structures that regulate multiple stages of the 
viral life cycle including transcription, splicing, gRNA 
dimerization, encapsidation and reverse transcription [8, 
10]. The central 8618 nt region encodes nine open read-
ing frames: gag, pol, vif, vpr, tat, rev, vpu, env and nef.
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In addition to encoding the amino acids of the viral 
proteins, the RNA sequence underlying the open read-
ing frames could regulate multiple steps of the HIV-1 
life cycle including splicing, RNA stability, RNA nuclear 
export, translation and reverse transcription. Indeed, 
a large number of cis-acting RNA elements within the 
protein coding regions have been reported to regulate 
HIV-1 replication, some of which are highly conserved 
and under purifying selection [11, 12]. These include 
the programmed ribosomal frameshift sequence in gag 
for Pol translation [13], splicing signals in pol, vif, vpr, 
tat, rev and env [2, 3], the Rev-response element (RRE) 
in env [14] and the polypurine tracts in pol and nef that 
are necessary for reverse transcription [15]. There is 
also extensive secondary and tertiary RNA structure 
throughout the gRNA that could regulate viral replica-
tion [16–19].
Determining the full complement of cis-acting ele-
ments in the gRNA that regulate viral replication is 
necessary for a complete understanding of the HIV-1 
replication cycle and may aid in the development of 
novel antiviral therapies [20]. Furthermore, identifying 
and characterizing evolutionarily conserved cis-acting 
elements and structures is essential for understanding 
HIV-1 purifying and positive selection as well as recom-
bination events [11, 12, 21–24]. Gag consists of four pro-
tein domains and two spacer peptides that control virion 
assembly [25]. Matrix (MA/p17) mediates Gag traffick-
ing to the plasma membrane, capsid (CA/p24) forms the 
structure of the virion core, nucleocapsid (NC/p7) binds 
the genomic RNA to mediate encapsidation, and p6 
recruits the ESCRT complexes necessary for membrane 
fission during budding. Within the MA open reading 
frame, there are a large number of proposed cis-acting 
RNA elements that could be necessary for viral replica-
tion. These include a hnRNPA1 binding site that may 
regulate gRNA nuclear export [26], an intronic splice 
enhancer [27, 28], an internal ribosome entry site [29], 
instability sequences that lead to RNA degradation in the 
absence of Rev [30], sequences that base pair with the 5′ 
and 3′ UTRs [31–35], and elements that regulate encap-
sidation [7, 8]. However, the functional relevance of most 
of these elements for viral replication is unclear.
Some nucleotide patterns may also regulate HIV-1 rep-
lication and be under evolutionary selection. For exam-
ple, the base composition of HIV-1 deviates from that of 
the human genome. HIV-1 RNA has a high percentage 
of adenine (A, 36%) and low percentage of cytosine (C, 
18%) [36–43]. This nucleotide bias is found in groups 
M, N and O and is a general property of lentiviruses, 
though not all retroviruses [36, 38, 42, 44]. Even though 
HIV-1 has a very high nucleotide substitution rate and 
sequence diversity, the A-rich bias has been conserved 
during the HIV-1 pandemic [42]. There are two hypoth-
eses for why this has been maintained in the virus. First, 
the mutational pattern of reverse transcriptase or antivi-
ral APOBEC3 proteins could impose an A-rich nucleo-
tide bias [45–52]. Second, this bias could be required for 
viral replication and be under purifying selection [38, 53, 
54].
In addition to understanding the RNA elements that 
are necessary for viral replication, it is important to char-
acterize the motifs that are underrepresented and may 
be deleterious. HIV-1 has a much lower than expected 
frequency of the dinucleotide CpG [36, 40, 44, 55–57]. 
This has been proposed to be under negative selection 
and the CpG dinucleotide abundance in HIV-1 may be 
linked to disease progression [58]. However, the mecha-
nism by which CpG dinucleotides affect viral replication 
is unknown.
These nucleotide biases cause the HIV-1 open reading 
frames to have a codon usage pattern that differs sub-
stantially from that of human mRNAs [36–41, 43]. The 
genetic code is redundant in that there are 61 codons for 
20 amino acids and all of the amino acids except methio-
nine and tryptophan are encoded by at least two codons. 
The preferred codons in cellular mRNAs are thought to 
correlate with the availability of the aminoacyl-tRNAs 
but HIV-1 contains many rare codons [36–41].
In this study, we investigated whether RNA elements 
in the MA region of gag positively or negatively regulate 
HIV-1 replication. We initially focused on this region 
because of its high content of potential RNA regula-
tory elements (discussed above). To change the RNA 
sequence without altering the amino acid sequence, we 
codon modified this region by introducing large num-
bers of synonymous mutations. These mutations strongly 
inhibited viral replication by decreasing gRNA abun-
dance, gRNA stability, Gag expression, virion produc-
tion and infectivity. We found that CpG dinucleotides 
introduced during codon modification were necessary 
and sufficient to attenuate HIV-1 replication. This high-
lights the functional importance of the suppressed CpG 
abundance in HIV-1 [36, 40, 44, 55–57] and shows that 
increasing the number of CpG dinucleotides in the gRNA 
inhibits multiple steps of the viral life cycle.
Methods
Cell culture and transfections
Jurkat cells were cultured in RPMI 1640 GlutaMAX 
Medium (Gibco) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin–streptomycin. Hela, 
TZM-bl and 293T cells were cultured in Dulbecco’s 
Modified Eagle Medium (Gibco) supplemented with 10% 
FBS and 1% penicillin–streptomycin. All cell lines were 
grown at 37 °C in a humidified atmosphere with 5%  CO2.
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Plasmids
The pHIV-1NL4-3 constructs used in this study contain 
the provirus sequence from pHIV-1NL4-3 [9] cloned into 
the KpnI and SalI sites of pGL4.10 (Promega). pHIV-1 
CM22-261, pHIV-1 CM22-165, pHIV-1 CM166-261 
and pHIV-1 CM22-378 have the designated sequences 
from pHDMHgpm2 [59] chemically synthesized by Life 
Technologies and cloned into pHIV-1NL4-3. For pHIV-
1CM 22-261lowCpG and pHIV-1 CM22-378lowCpG, pHIV-1 
CpG22-261 and pHIV-1 CpG22-378, the sequences 
shown in Fig.  6 were synthesized by Life Technolo-
gies and cloned into pHIV-1NL4-3. pHIV-1 ∆22-261 and 
pHIV-1 ∆22-378 have the designated region in gag 
replaced with a XbaI site as in Reil et al. [60]. The modi-
fied sequences in these plasmids were verified by DNA 
sequencing (Eurofins). pGFP and pVSV-G have been pre-
viously described [61, 62].
HIV‑1 spreading infection assay
4 × 106 293T cells were seeded in 10 cm plates and trans-
fected with 10 μg of pHIV-1 and 1.25 μg of pGFP using 
poly(ethlyleneimine) solution (PEI) at a ratio of 5 μl PEI 
per 1  μg DNA. Approximately 48-h post-transfection, 
the media was harvested, filtered through a 0.45 μm fil-
ter and quantified using a  p24Gag enzyme-linked immu-
nosorbent assay (ELISA) (Perkin-Elmer). A total of 
2.5 × 105 Jurkat cells were plated in 1 mL of medium per 
well in 48 well plates and infected with 25 ng of  p24Gag 
of each virus. SupT1 cells were infected with 10  ng of 
 p24Gag for each virus. Supernatants were first collected 
when syncytia were first observed in the culture infected 
with HIV-1NL4-3. The amount of infectious virus present 
at each time point was quantified by infecting the TZM-
bl indicator cell line [63–65]. Infectivity was measured by 
the induction of β-galactosidase using the Galacto-Star™ 
System (Applied Biosystems).
Single cycle infectivity assay
Six-well plates of HeLa cells were transfected using 
 TransIT®-LT1 (Mirus) according to the manufacturer’s 
instructions at the ratio of 3 μL  TransIT®-LT1 to 1  μg 
DNA. For each transfection, 0.5  μg pHIV-1 and 0.5  μg 
pGFP or pVSV-G was used. Media was recovered approx-
imately 48  h post-transfection and filtered through a 
20% sucrose cushion for 2 h at 20,000×g. The amount of 
infectious virus was quantified by using the TZM-bl indi-
cator cell line [63–65].
Analysis of protein expression by immunoblotting
Approximately 48-h post-transfection, HeLa cells were 
lysed in radioimmunoprecipitation assay (RIPA) buffer 
(10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate). 
The media was clarified using a 0.45  μm filter. Virions 
were pelleted through a 20% sucrose cushion in phos-
phate-buffered saline (PBS) solution for 2 h at 20,000×g. 
The pellet was resuspended in 2× loading buffer (60 mM 
Tris–HCl (pH 6.8), 10% β-mercaptoethanol, 10% glyc-
erol, 2% sodium dodecyl sulfate (SDS), 0.1% bromo-
phenol blue). Cell lysates and virions were resolved by 
SDS–polyacrylamide gel electrophoresis and transferred 
to a nitrocellulose membrane. The primary antibodies 
used were specific to HIV-1  p24Gag [66], Hsp90 (sc7947: 
Santa Cruz Biotechnology), phosphoSTAT1 (612132: BD 
Transduction), IFIT1 (GTX118713-S: Insight Biotechnol-
ogy) or β-actin (ac-15: Sigma). Dylight™ 800-conjugated 
secondary antibodies (5151S and 5257S: Cell Signaling) 
were used to detect the bound primary antibodies with 
the Li-CoR infrared imaging (LI-COR UK LTD).
Quantitative RT‑PCR
Hela cells were washed with 1xPBS and the RNA was 
extracted using the RNeasy kit (Qiagen) following the 
manufacturer’s instructions. 1  μg of RNA was reverse 
transcribed to cDNA using the High Capacity cDNA 
archive kit (Applied Biosystems). RNA from virions 
was isolated using QIAamp viral RNA mini kit follow-
ing the manufacturer’s instructions. Because carrier 
RNA is added to the lysis buffer, the total RNA isolated 
was quantified using a Qubit 3.0 fluorometer (Ther-
moFisher) and normalized so that 20  ng of RNA from 
each sample was reverse transcribed using the High 
Capacity cDNA archive kit (Applied Biosystems). PCR 
reactions were performed in triplicate with Taqman 
Universal PCR mix using the Applied Biosystems 7500 
real-time PCR system. HIV-1NL4-3 gRNA primers were 
GGCCAGGGAATTTTCTTCAGA/TTGTCTCTTCC-
CCAAACCTGA (forward/reverse) and the probe was 
FAM-ACCAGAGCCAACAGCCCCACCAGA-TAMRA. 
HIV-1NL4-3 total RNA primers were TAACTAGG-
GAACCCACTGC/GCTAGAGATTTTCCACACTG 
(forward/reverse) and the probe was FAM-ACACAA-
CAGACGGGCACACACTA-TAMRA. To analyze gRNA 
stability, 1  µg/ml Actinomycin D (Sigma Aldrich) was 
added to HeLa cells ~ 45 h post-transfection. RNA was 
isolated at the designated timepoints and gRNA abun-
dance was measured.
TLR and IFN stimulations, Sendai virus infection
HeLa cells were stimulated with synthetic TLR ligands 
for 5 h at the concentrations indicated. Ligands supplied 
by Invivogen were polyIC: polyIC (tlrl-pic), Gardiquimod 
(tlrl-gdqs), CL075 (tlrl-c75), R848 (tlrl-r848), Pam3CSK4 
(P3C. tlrl-pms), Ultrapure Flagellin (FliC-tlrl-epstfla-5). 
LPS was supplied by Enzo (ALX-581-012-L002). CpG 
DNA was synthesised by IDT and 23S ribosomal RNA 
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by Sigma. Sendai Virus (SeV) was obtained from Charles 
River labs. IFN-β was purchased from Peprotech and was 
added to the culture for 1 h to activate IFN signaling.
Sequence analysis of the HIV‑1NL4‑3 gRNA
The “analyze base composition” tool in MacVector was 
used to calculate the mono- and di-nucleotide frequen-
cies for the HIV-1NL4-3 gRNA (NCBI accession number 
M19921). The dinucleotide frequencies are calculated 
using the following formula: number of dinucleotide 
occurrences/(frequency of base 1 in pair  ×  frequency 
of base 2 in pair) where frequency of base is number of 
occurrences of base/total number of bases in sequence. 
WebLogo [67] was used to generate conserved nucleo-
tides surrounding the CpG dinucleotides.
Results
Synonymous mutations in gag inhibit HIV‑1 replication
To analyze the functional relevance of RNA elements and 
nucleotide bias underlying the MA domain in Gag, we 
introduced 80 synonymous mutations into nt 22-261 of 
HIV-1NL4-3 gag (Fig. 1a). This codon modified (CM) pro-
virus, HIV-1 CM22-261, has 69/80 codons in this region 
altered without affecting the amino acid sequence. The 
mutations were derived from pHDMHgpm2, a codon 
optimized Gag-Pol construct in which many of the 
HIV-1 codons are replaced with codons used in highly 
expressed human mRNAs [59, 68]. In addition, nt 22-165 
or 166-261 in gag were codon modified to produce HIV-1 
CM22-165 and HIV-1 CM166-216, which have 49 and 31 
synonymous mutations, respectively. Virus stocks were 
prepared by transfecting 293T cells with each proviral 
DNA construct and the concentration of viral CA/p24Gag 
for each stock was measured by ELISA. HIV-1 CM22-
261 and HIV-1 CM22-165 had an  ~  65% and  ~  40% 
decrease in  p24Gag concentration, respectively (Fig.  1b). 
To analyze the fitness of each virus, the viral inoculum 
was normalized so that Jurkat CD4 T cells were chal-
lenged with 25 ng of  p24Gag for each virus (Fig. 1c). The 
amount of infectious virus in the culture supernatant 
was monitored over 2  weeks using TZM-bl indicator 
cells [63–65]. HIV-1 CM22-261 replicated at a very low 
but detectable level and at day 12 had > 99.9% less infec-
tivity than wild type virus. HIV-1 CM22-165 replicated 
slightly better than HIV-1 CM22-261, but was still > 99% 
lower than wild type HIV-1 at day 12. HIV-1 CM166-261 
plateaued at the same level as wild type HIV-1 but with 
a delay of ~ 3 days. Similar results were observed when 
SupT1 CD4 T cells were challenged with the wild type 
and mutated viruses (Additional file 1).
We then used a single cycle infectivity assay to deter-
mine if HeLa cells were non-permissive for HIV-1 CM22-
261, HIV CM22-165 or HIV-1 CM166-261 replication as 
well as to characterize which steps in the viral life cycle 
are inhibited by the synonymous changes in gag. HeLa 
cells were transfected with pHIV-1NL4-3, pHIV-1 CM22-
261, pHIV-1 CM22-165 or pHIV-1 CM166-261 and the 
media and cell lysates were harvested ~ 48 h later. HIV-1 
infectivity in the media was determined using TZM-bl 
cells and the abundance of virions in the media and Gag 
in the cell lysate was analyzed by quantitative immunob-
lotting. Compared with the wild type virus, HIV-1 CM22-
261 infectivity was decreased to the limit of detection of 
the assay (Fig.  2a), indicating that the virus is attenuated 
in HeLa cells. Virion production and intracellular Gag 
expression were decreased  ~  90% (Fig.  2b, c). For HIV-1 
CM22-165, the amount of infectious virus in the media 
was decreased ~ 98% with a < 50% decrease in Gag expres-
sion and viron production. HIV-1 CM166-261 consistently 
yielded similar amounts of infectivity, virions and intracel-
lular Gag expression as wild type HIV-1. Overall, there is 
a substantial reduction in infectivity for HIV-1 CM22-261 
and HIV-1 CM22-165. HIV-1 CM22-261 also has a sub-
stantial defect in Gag expression and virion production.
To determine if the decrease in infectious virus pro-
duction was due to a decrease in gRNA abundance, we 
performed quantitative RT-PCR (qRT-PCR) using a 
primer–probe set in a region of gag that was not mutated 
(Fig.  3a, b). pHIV-1NL4-3, pHIV-1 CM22-261, pHIV-1 
CM22-165 and pHIV-1 CM22166-261 were transfected 
into HeLa cells. RNA was isolated from the cell lysate and 
media ~ 48 h post-transfection. HIV-1 CM22-261 gRNA 
was reduced  >  90% in the cell lysate and media com-
pared with the wild type virus. HIV-1 CM22-165 gRNA 
was decreased ~ 70% in the cell and ~ 65% in the media. 
HIV-1 CM166-261 gRNA abundance was equivalent to 
wild type HIV-1 in the cell lysate and media. We then 
determined the effect of the synonymous mutations on 
infectivity/viral genome by infecting TZM-bl cells with 
an equivalent amount of viral genomes for each virus. 
When the input number of genomes was normalized 
based on the results in Fig. 3b, HIV-1 CM22-261 infectiv-
ity was at the limit of detection of the assay and HIV-1 
CM22-165 infectivity was decreased ~ 98% (Fig. 3c). This 
indicates that the decreased abundance of viral genomes 
in the media is not fully responsible for the loss of infec-
tivity for HIV-1 CM22-261 and HIV-1 CM22-165.
The HIV-1 gRNA can be spliced into over 70 differ-
ent transcripts [4] and the gag-pol intron can be spliced 
out through one 5′ splice site and six 3′ splice sites [2]. 
A potential explanation for the decrease in intracellu-
lar gRNA abundance is that the mutations in gag could 
affect intronic splicing silencer (ISS) sequences. If this 
occurred, gRNA abundance would decrease due to 
oversplicing but the total amount of HIV-1 RNA would 
stay the same. To test this, we determined the total 
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intracellular HIV-1 RNA abundance using a primer–
probe set upstream of the major 5′ splice donor (SD1). 
HIV-1 CM22-261 and HIV-1 CM22-165 had an  ~  80 
and  ~  60% decrease in total HIV-1 RNA abundance 
(Additional file  2). Since  ~  50% of the gRNA remains 
unspliced [2], this is consistent with a specific reduction 
in the gRNA and does not appear to be a consequence of 
oversplicing.
CpG dinucleotides are necessary for the inhibition 
of infectious virus production
The synonymous mutations introduced into gag could 
inhibit HIV-1 replication by inactivating essential cis-
acting RNA elements or introducing inhibitory elements. 
The region mutated in HIV-1 CM22-261 was designed to 
match the codons previously deleted by Reil et al. [60] in 
HIV-1HXBH10∆8-87/∆CT. In this virus, amino acids 8-87 
Fig. 1 Codon modification of nucleotides 22‑261 in gag inhibits viral replication. a Schematic representation of  p55Gag in HIV‑1NL4‑3, HIV‑1 CM22‑
261, HIV‑1 CM22‑165 and HIV‑1 CM166‑261. b The amount of HIV‑1 CA  (p24Gag) in supernatants from 293T cells transfected with pHIV‑1NL4‑3, pHIV‑1 
CM22‑261, pHIV‑1 CM22‑165 or pHIV‑1 CM166‑261 were quantified by  p24Gag ELISA. The bar chart is the average of three independent experiments 
normalized to HIV‑1NL4‑3. Error bars represent standard deviation. c Jurkat cells were infected with 25 ng of  p24
Gag for each indicated virus. The 
amount of infectious virus present at each time point was measured in TZM‑bl cells. This is representative of three independent experiments
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Fig. 2 Codon modification of nucleotides 22‑261 in gag inhibits infectious virus production. HeLa cells were transfected with pHIV‑1NL4‑3, pHIV‑1 
CM22‑261, pHIV‑1 CM22‑165 or pHIV‑1 CM166‑261. a Culture supernatants were used to infect TZM‑bl reporter cells to measure viral infectivity. 
The bar charts show the average values of six independent experiments normalized to the value obtained for HIV‑1NL4‑3. The average relative light 
units (RLU) for HIV‑1NL4‑3 is 3,680,747. The dashed line represents 1000 RLU, which is approximately the limit of the assay for reproducible differential 
results. Error bars represent standard deviation. b, c Gag expression in the media (b) and cell lysate (c) was detected using quantitative immunoblot‑
ting. The bar charts show the average of four independent experiments normalized to HIV‑1NL4‑3. Error bars represent standard deviation
Fig. 3 Codon modification of nucleotides 22‑261 in gag decreases gRNA abundance. HeLa cells were transfected with pHIV‑1NL4‑3, pHIV‑1 CM22‑
261, pHIV‑1 CM22‑165 or pHIV‑1 CM166‑261. The bar charts show the average values of three independent experiments normalized to HIV‑1NL4‑3. 
Error bars represent standard deviation. a RNA was extracted from cell lysates and gRNA abundance was quantified by qRT‑PCR. b RNA was 
extracted from the media and gRNA abundance was quantified by qRT‑PCR. c Equivalent amounts of HIV‑1 genomes were used to infect TZM‑bl 
reporter cells to measure infectivity. The bar charts show the average values of three independent experiments normalized to the value obtained 
for HIV‑1NL4‑3. The average RLU for HIV‑1NL4‑3 is 1,146,196. The dashed line represents 1000 RLU, which is approximately the limit of the assay for 
reproducible differential results
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(nt 22-261) in Gag were deleted and a stop codon in Env 
removed the cytoplasmic tail domain. Because deletions 
in the globular core domain of MA prevent incorporation 
of Env with a full cytoplasmic domain [69], the truncated 
Env cytoplasmic tail is necessary for virion infectivity. 
However, pseudotyping with heterologous envelope gly-
coproteins, such as that from vesicular stomatitis virus 
(VSV-G), allow viral entry into a target cell. HIV-1HXBH10 
∆8-87/∆CT replicates as well as HIV-1HXBH10 ∆CT in the 
MT4 cell line [60], indicating that neither the protein or 
RNA sequences in this region are necessary for viral rep-
lication in these cells.
To determine whether the synonymous mutations 
inserted into nt 22-261 of gag removed essential cis-
acting elements or inserted deleterious sequences, we 
generated a HIV-1NL4-3 ∆22-261 provirus construct 
(Fig.  4a) and compared it with HIV-1 CM22-261 in the 
absence or presence of VSV-G. In the absence of VSV-
G, HIV-1 ∆22-261 produced very low levels of infec-
tious virus (Fig. 4b), which was expected due to the role 
of MA in recruiting Env with a full-length cytoplasmic 
tail. Gag expression and virion production were similar 
for wild type HIV-1 and HIV-1 ∆22-261 (Fig.  4c), indi-
cating that RNA or protein sequences in this region are 
not necessary for these steps of the viral life cycle. When 
the viruses were pseudotyped with VSV-G, HIV-1 ∆22-
261 infectivity was similar to wild type virus, confirming 
that the only functional defect for this virus in HeLa cells 
is Env incorporation. In contrast, HIV-1 CM22-261 was 
not rescued by VSV-G pseudotyping and had a > 99.9% 
reduction in infectivity (Fig. 4d).
Reil et  al. [60] also deleted amino acids 8-126 (nt 
22-378) in MA and found that HIV-1HXBH10 ∆8-126/∆CT 
replicated with moderately delayed kinetics compared 
to HIV-1HXBH10 ∆CT in MT4 cells. We produced HIV-
1NL4-3 provirus constructs in which this region was either 
deleted (HIV-1 ∆22-378) or codon modified (HIV-1 
CM22-378). VSV-G pseudotyped HIV-1 ∆22-378 had a 
small decrease in infectious virus production compared 
to wild type HIV-1 (Fig. 4d), which correlated with virion 
production (Fig.  4e). However, VSV-G pseudotyped 
HIV-1 CM22-378 had a  >  99.9% decrease in infectious 
virus production with Gag expression and virion produc-
tion near the limit of detection (Fig. 4d, e). Therefore, we 
concluded that codon modification of nt 22-261 or nt 
22-378 of gag introduced inhibitory sequences into the 
HIV-1 genome that reduce Gag expression, virion pro-
duction and infectivity.
To determine whether the synonymous mutations 
in gag altered the stability of the viral RNA, HeLa cells 
were transfected with pHIV-1NL4-3, pHIV-1 CM22-261 or 
pHIV-1 CM22-378 and,  ~  45  h post-transfection, RNA 
polymerase II-dependent transcription was inhibited 
by adding actinomycin D. RNA was isolated from the 
cells immediately before actinomycin D addition (0  h) 
and then 1, 2, 4 and 6 h thereafter. gRNA abundance at 
the 0 h timepoint was substantially decreased for HIV-1 
CM22-261 and HIV-1 CM22-378 (Fig.  5a) and corre-
lated with the length of codon modified sequence. Since 
MYC mRNA has a half-life of < 1 h [70], we used it as a 
control for RNA stability and analyzed its abundance at 
each timepoint. As expected, MYC mRNA was rapidly 
degraded (Fig. 5b). The gRNA abundance for HIV-1NL4-3, 
HIV-1 CM22-261 and HIV-1 CM22-378 decreased 
by  ~  20,  ~  35 and  ~  70%, respectively, at the 6  h time-
point relative to its abundance at 0 h (Fig. 5c). This indi-
cates that HIV-1 CM22-261 and HIV-1 CM22-378 gRNA 
is less stable than HIV-1NL4-3 gRNA. Comparing HIV-1 
CM22-378 gRNA abundance to that of HIV-1NL4-3 at the 
6 h timepoint, HIV-1 CM22-378 gRNA was ~ 60% lower 
than wild type virus gRNA. If the degradation rate is con-
stant, a 50% decrease every 6 h in gRNA abundance for 
HIV-1 CM22-378 relative to HIV-1NL4-3 would be com-
pounded to yield a 98.4% decrease after 36 h. This is con-
sistent with the ~ 98% decrease in steady state gRNA for 
HIV-1 CM22-378 that we observed ~ 45 h post-transfec-
tion (Fig. 5a). Overall, the synonymous mutations intro-
duced into gag appear to decrease the stability of the 
gRNA.
Two types of RNA dinucleotide patterns have previ-
ously been implicated in restricting RNA virus replica-
tion, UpA and CpG [71–74]. The observed/expected 
ratio for UpA in the HIV-1NL4-3 gRNA is 0.92 (Table  1) 
and the total number of UpA dinucleotides in nt 22-261 
and 22-378 decreased substantially in the codon modi-
fied sequence compared with the wild type sequence 
(Table  2). This indicates that UpA dinucleotide con-
tent is not causing the inhibitory phenotype. The CpG 
dinucleotide observed/expected ratio is 0.21 in HIV-
1NL4-3 and it is the only dinucleotide substantially sup-
pressed (Table  1). Within nt 22-261 of gag, wild type 
HIV-1 has 4 CpG dinucleotides and the codon modified 
sequence has 22 (Table  2). Similarly, codon modifica-
tion of nt 22-378 increased the number of CpGs from 4 
to 30. Because CpG dinucleotides are underrepresented 
in HIV-1 (Table 1) [40, 44, 55–57] and previous reports 
have shown that increasing the CpG dinucleotide abun-
dance inhibits picornavirus and influenza virus replica-
tion [71–74], we hypothesized that the increased number 
of CpG dinucleotides in HIV-1 CM22-261 and HIV-1 
CM22-378 could cause the decrease in HIV-1 infectious 
virion production.
To test this hypothesis, we synthesized a HIV-1 gag 
sequence containing all of the synonymous muta-
tions present in pHIV CM22-261 with the exception of 
the codon changes that introduced CpG dinucleotides 
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Fig. 4 Codon modification but not deletion of nucleotides 22‑261 or 22‑378 in gag inhibits infectious virus production. a Schematic representation 
of  p55Gag in HIV‑1NL4‑3, HIV‑1 CM22‑261, HIV‑1 Δ22‑261, HIV‑1 CM22‑378 or HIV‑1 Δ22‑378. b, d HeLa cells were transfected with pHIV‑1NL4‑3, pHIV‑1 
CM22‑261, pHIV‑1 Δ22‑261, pHIV‑1 CM22‑378 or pHIV‑1 Δ22‑378 and pGFP (b) or pVSV‑G (d). The amount of infectious virus in the culture super‑
natants was measured in TZM‑bl cells. The average RLU for HIV‑1NL4‑3 + GFP and HIV‑1NL4‑3 + VSV‑G is 13,701,427 and 16,981,387, respectively. The 
dashed line represents 1000 RLU, which is approximately the limit of the assay for reproducible differential results. c, e Gag expression in the media 
and cell lysate were measured by quantitative western blotting. b–e The bar charts show the average of three independent experiments relative to 
HIV‑1NL4‑3. Error bars represent standard deviation
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(Fig. 6) and inserted it into  pHIVNL4-3 to produce pHIV-1 
CM22-261lowCpG. Within nt 22-261 of gag, HIV-1 CM22-
261lowCpG has the same four CpG dinucleotides as wild 
type HIV-1 and 59 mutations, compared with HIV-1 
CM 22-261 that has 22 CpG dinucleotides and 80 muta-
tions (Fig.  6, Table  2). pHIV-1NL4-3, pHIV-1 CM22-261 
and pHIV-1 CM22-261lowCpG were transfected into HeLa 
cells and single round infectivity assays were performed. 
In contrast to HIV-1 CM22-261, HIV-1 CM22-261lowCpG 
infectivity, Gag expression and virion production was 
similar to HIV-1NL4-3 (Fig. 7a, b). We also cloned pHIV-1 
CM22-378lowCpG, which has four CpG dinucleotides and 
79 mutations compared with the 30 CpG dinucleotides 
and 109 mutations in HIV-1 CM22-378 (Fig. 6, Table 2). 
In a single round infectivity assay, HIV-1 CM22-378lowCpG 
also had similar levels of infectivity, intracellular Gag 
expression and virion production as HIV-1NL4-3 (Fig. 7c, 
d). While codon modification of nt 22-261 and 22-378 in 
gag substantially decreased the A-rich nucleotide bias of 
these regions, eliminating only the CpG dinucleotides in 
the codon modified sequence did not restore the A-rich 
bias for HIV-1 CM 22-261lowCpG and HIV-1 CM22-
378lowCpG (Table 2). This supports the hypothesis that the 
decrease in infectivity for HIV-1 CM22-261 and HIV-1 
CM22-378 is due to the introduced CpG dinucleotides 
and not changes in the A-rich nucleotide bias. In sum, 
changing the codons that introduced CpG dinucleotides 
in nt 22-261 or nt 22-378 back to the wild type HIV-1 
codons while maintaining all of the other mutations in 
these regions restored infectious virus production.
Toll-like receptor 9 (TLR9) recognizes unmethylated 
CpG DNA motifs in endolysosomes within plasmacy-
toid dendritic cells, macrophages, and B cells [75]. Upon 
ligand binding, TLR9 signaling stimulates interferon 
alpha (IFN-α) production, which binds the interferon 
alpha and beta receptor (IFNAR) and induces interferon 
stimulated gene (ISG) expression via the JAK-STAT 
signaling pathway. To determine whether HeLa cells are 
responsive to CpG DNA or other TLR ligands, we tested 
a panel of ligands for TLR2, TLR3, TLR4, TLR5, TLR7, 
TLR8, TLR9 and TLR13 (Additional file  3). As positive 
controls, HeLa cells were infected with Sendai virus, 
which activates the cytoplasmic RNA sensors RIG-I and 
MDA5 (RIG-I-like receptors, RLR), or were treated with 
interferon beta (IFN-β), which also binds IFNAR. Both 
Sendai virus and IFN-β stimulated STAT1 phosphoryla-
tion and IFIT1 expression, which is an ISG. CpG DNA 
did not stimulate STAT1 phosphorylation or IFIT1 
expression. The only TLR ligand that stimulated the 
cells was poly(I:C), which is structurally similar to dou-
ble stranded RNA and can also signal via RLRs. There-
fore, it is unlikely that the additional CpG dinucleotides 
in HIV-1 CM22-261 and HIV-1 CM22-378 inhibit viral 
replication via TLR9 or other TLRs in HeLa cells.
Increased abundance of CpG dinucleotides is sufficient 
for inhibition of viral replication
To determine if increasing the abundance of CpG dinu-
cleotides is sufficient to inhibit HIV-1 replication, we 
synthesized gag sequences in which only the codons 
that introduced CpG dinucleotides in the codon modi-
fied sequence were changed (Fig. 6). These were inserted 
into  pHIVNL4-3 to produce pHIV-1 CpG22-165, pHIV-1 
CpG22-261 and pHIV-1 CpG22-378. We then used a 
spreading infection assay in Jurkat cells to analyze the 
effect of the increased CpG abundance. 293T cells were 
transfected with each proviral construct to produce 
stocks of each virus and the abundance of  p24Gag was 
Fig. 5 Codon modification of nucleotides 22‑261 and 22‑378 in gag 
decreases gRNA abundance and stability. HeLa cells were transfected 
with pHIV‑1NL4‑3, pHIV‑1 CM22‑261 or pHIV‑1 CM22‑378. a RNA was 
extracted from cell lysates at the 0 h timepoint and gRNA abundance 
was quantified by qRT‑PCR. The bar charts show the average values 
of three independent experiments normalized to HIV‑1NL4‑3. Error 
bars represent standard deviation. b, c Actinomycin D was added 
to inhibit RNA polymerase II transcription and the abundance of 
MYC mRNA (b) or gRNA (c) was measured at 0, 1, 2, 4 and 6 h post‑
addition. Each value is relative to the 0 h timepoint and is an average 
of three independent experiments. Error bars represent standard 
deviation
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measured for each by ELISA. HIV-1 CpG22-165 and 
HIV-1 CpG22-261 produced similar amounts of virus 
to HIV-1NL4-3 while HIV-1 CpG22-378 virus production 
was decreased by ~ 70% (Fig. 8a). The viral inoculum was 
normalized so that Jurkat cells were infected with 25 ng 
of  p24Gag for each virus and replication was monitored 
over ~ 2 weeks. There are an additional 11 CpG dinucleo-
tides in HIV-1 CpG22-165 and its replication was sub-
stantially reduced, with  >  90% less infectivity at Day 13 
compared to HIV-1NL4-3 (Fig. 8b). HIV-1 CpG22-261 has 
an additional 18 CpG dinucleotides and HIV-1 CpG22-
378 has an additional 26 CpG dinucleotides. Neither 
Table 1 HIV‑1NL4‑3 genomic RNA mononucleotide and dinucleotide frequencies
Base # Freq. % Obs./Exp.
Mononucleotide frequencies
 A 3281 0.358 35.8 1.43
 C 1635 0.178 17.8 0.71
 G 2216 0.242 24.2 0.97
 T 2041 0.223 22.3 0.89
 G + C 3851 0.420 42.0 0.84
 A + T 5322 0.580 58.0 1.16
Total positions = 9173
Base # Freq. % Obs./Exp.
Dinucleotide frequencies
 AA 1093 0.119 11.9 0.93
 AC 522 0.057 5.7 0.89
 AG 962 0.105 10.5 1.21
 AT 703 0.077 7.7 0.96
 CA 758 0.083 8.3 1.30
 CC 371 0.040 4.0 1.27
 CG 82 0.009 0.9 0.21
 CT 424 0.046 4.6 1.17
 GA 762 0.083 8.3 0.96
 GC 424 0.046 4.6 1.07
 GG 625 0.068 6.8 1.17
 GT 405 0.044 4.4 0.82
 TA 668 0.073 7.3 0.92
 TC 318 0.035 3.5 0.87
 TG 546 0.060 6.0 1.11
 TT 509 0.055 5.5 1.12
Total positions = 9172
Table 2 Changes in  nucleotide composition and  total number of  mutations for  codon modification of  regions 22‑261 
and 22‑378 in gag
Construct % A % C % G % T Total UpA Total CpG Total number mutations relative to wild type
WT 22‑261 38 17 23 22 23 4
CM 22‑261 18 36 32 15 3 22 80
CM 22‑261lowCpG 24 27 34 15 5 4 59
CpG 22‑261 32 25 22 21 19 22 21
WT 22‑378 42 17 24 18 29 4
CM 22‑378 22 35 32 12 3 30 109
CM 22‑378lowCpG 28 26 33 13 7 4 79
CpG 22‑378 36 25 22 17 23 30 30
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of these viruses replicated in the Jurkat cells (Fig.  8b). 
Therefore, introducing CpG dinucleotides into HIV-1 gag 
is sufficient to strongly attenuate viral replication in Jur-
kat cells.
To analyze the steps of the HIV-1 life cycle that were 
inhibited by the CpG dinucleotides, HeLa cells were 
transfected with  pHIVNL4-3, pHIV-1 CpG22-165, pHIV-1 
CpG22-261 or pHIV-1 CpG22-378.  ~  48  h later, the 
media and cell lysates were harvested for infectivity, pro-
tein or RNA analysis. In this single cycle assay, HIV-1 
CpG22-378 infectivity was decreased  ~  99% (Fig.  9a). 
While there was no change in Gag expression or virion 
production (Fig.  9b), HIV-1 CpG22-378 gRNA was 
decreased ~ 40% in the cell lysate and ~ 80% in the media 
(Fig. 9c, d). HIV-1 CpG22-261 had a ~ 75% decrease in 
infectivity with no difference in Gag expression, virion 
production or gRNA abundance (Fig.  9a–d). There was 
no decrease in infectious virus production for HIV-1 
CpG 22-165. Overall, introducing 26 CpG dinucleo-
tides into  HIVNL4-3 decreased infectious virus produc-
tion by ~ 99%, though this is a smaller attenuation than 
viruses containing CpG dinucleotides in the context of 
the codon modified sequence (Figs. 2, 4, 7).
One potential explanation for why HIV-1 containing 
CpG dinucleotides in a codon modified context produce 
less infectious virus in HeLa cells than HIV-1 in which 
Fig. 6 Schematic representation of nucleotides 1‑420 in gag for HIV‑1NL4‑3, HIV‑1 CM22‑261, HIV‑1 CM22‑165, HIV‑1 CM166‑261, HIV‑1CM22‑261low‑
CpG, HIV‑1 CM22‑378 and HIV‑1 CM22‑378lowCpG. Mutations that are the result of codon modification and do not introduce CpG dinucleotides are 
highlighted in turquoise. CpG dinucleotides present in HIV‑1NL4‑3 are highlighted in yellow and CpG dinucleotides introduced by codon modification 
are highlighted in red
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only CpG dinucleotides have been added is that a nucleic 
acid binding protein could bind the CpG dinucleotide to 
mediate antiviral activity. If a protein does directly bind 
the CpG dinucleotide, its binding site may encompass 
more than just the CpG and the surrounding nucleotides 
may affect binding. Therefore, the five nucleotides 5′ and 
3′ of the introduced CpG in HIV-1 CM22-378 and HIV-1 
CpG22-378 were used to generate a 12 nt sequence. 
These were aligned and conserved nucleotides were iden-
tified using WebLogo [67]. Interestingly, the nucleotides 
surrounding the CpG in the codon modified sequence 
are more G/C-rich than in the wild type HIV-1 sequence 
(Additional file 4A and B).
Fig. 7 Decreasing the CpG abundance within HIV‑1 CM22‑261 and HIV‑1 CM22‑378 restores infectious virus production. HeLa cells were trans‑
fected with pHIV‑1NL4‑3, pHIV‑1 CM22‑261, pHIV‑1 CM22‑261lowCpG, pHIV‑1 CM22‑378 and pHIV‑1 CM22‑378lowCpG. The bar charts show the average 
of three independent experiments relative to HIV‑1NL4‑3. Error bars represent standard deviation. a, c The amount of infectious virus present in the 
media was measured in TZM‑bl cells. b, d Virion production and intracellular Gag expression was measured using quantitative western blotting
Page 13 of 18Antzin‑Anduetza et al. Retrovirology  (2017) 14:49 
Discussion
Herein, we show that introducing CpG dinucleotides into 
the HIV-1 genome inhibits viral replication. When only 
11 CpG dinucleotides are inserted into gag in the con-
text of the codon modified sequence (HIV-1 CM22-165), 
there is a large decrease in infectivity without a substan-
tial loss of gRNA abundance, Gag expression or virion 
production (Figs.  2, 3). When 18 or 26 CpG dinucleo-
tides are added (HIV-1 CM22-261 and HIV-1 CM22-378, 
respectively), the intracellular gRNA stability and abun-
dance is decreased which leads to reduced Gag expres-
sion and virion production (Figs. 2, 3, 4, 5). In addition, 
there is a defect in the pre-integration steps of the viral 
life cycle that is apparent when equivalent numbers of 
genomes are used to infect target cells (Fig.  3c). Thus, 
manipulating the CpG abundance in gag can impart both 
producer and target cell defects in replication. Determin-
ing whether these deficiencies are underpinned by a com-
mon mechanism such as shared host factors, or whether 
they are distinct from each other, will be an important 
direction of our future work.
Remarkably, none of the proposed cis-acting elements 
in nt 22-378 of gag appear to be necessary for infectious 
virus production in HeLa cells. We demonstrated this 
by comparing viruses that have nt 22-261 or nt 22-378 
codon modified or deleted (Fig.  4). While codon modi-
fication of these regions inhibited HIV-1 infectivity, 
deletion of the same region did not substantially impair 
infectivity in a single round assay. Furthermore, removing 
the introduced CpG dinucleotides in HIV-1 CM22-261 
and HIV-1 CM22-378 while maintaining either 59 or 79 
other nucleotide changes, respectively, almost completely 
restored HIV-1 infectious virus production (Fig. 7). This 
supports the observation by Reil et al. [60] that the glob-
ular head of MA can be deleted in the context of Env 
with a truncated cytoplasmic domain without substan-
tially impairing viral replication in the MT4 T cell line or 
virion production in HeLa cells.
One of the cis-acting elements proposed to be in the 
gag region that we have mutated is the gRNA packag-
ing signal. While a relatively short sequence sufficient 
for packaging heterologous transcripts into virions has 
been identified for rous sarcoma virus and murine leuke-
mia virus, delineation of the HIV-1 RNA sequence that is 
sufficient for packaging has been more controversial [7, 
8]. The core packaging signal for HIV-1 is in the 5′ UTR; 
however, approximately 300 nt of the 5′ end of gag has 
been proposed to improve viral titre [7, 8]. We did not 
codon modify the first 21 nt of gag because this region 
is under purifying selection [11, 12] and NMR structures 
have shown that it base pairs with the U5 region of the 5′ 
UTR to form the dimer promoting conformation of the 
gRNA that is packaged into virions [10, 76]. However, the 
relative importance of the sequence in gag beyond the 
first 21 nt for packaging the full-length HIV-1 gRNA, as 
opposed to heterologous transcripts, is unclear. Mapping 
Gag binding sites on the gRNA in living cells showed that 
the RNA elements most frequently crosslinked to Gag 
were in the 5′ UTR and the RRE [77]. In the context of 
the full-length virus, our data indicates that nt 22-378 in 
gag appear to have only a small effect on viral infectiv-
ity when this region is deleted or mutated without add-
ing CpG dinucleotides (Figs.  4, 7). The requirement for 
this region for gRNA packaging may be different in the 
context of lentiviral vector genomes, which contain only 
a small portion of the HIV-1 gRNA [78].
In principle, codon usage changes in gag could affect 
gRNA translation [79]. However, the translation effi-
ciency of a codon optimized gag mRNA is only  ~  1.6-
fold higher than wild type gag mRNA that contains 
theoretically suboptimal codon usage [80]. Our data 
indicate that gRNA translation efficiency is not substan-
tially affected by the changes in codon usage for HIV-1 
CM22-261 since Gag expression (Fig. 2c) and intracellu-
lar gRNA abundance (Figs.  3c, 5a) were both decreased 
by ~ 90%. Changing the RNA sequence could also affect 
Fig. 8 Introduction of CpG dinucleotides into gag inhibits HIV‑1 
replication in Jurkat cells. a The amount of HIV‑1 CA  (p24Gag) in 
supernatants from 293T cells transfected with pHIV‑1NL4‑3, pHIV‑1 
CpG22‑165, pHIV‑1 CpG22‑261 or pHIV‑1 CpG22‑378 were quantified 
by  p24Gag ELISA. The bar chart is the average of three independent 
experiments normalized to HIV‑1NL4‑3. Error bars represent standard 
deviation. b Jurkat cells were infected with 25 ng of  p24Gag for each 
indicated virus. The amount of infectious virus present at each time 
point was measured in TZM‑bl cells. This is representative of three 
independent experiments
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the secondary or tertiary structure of the gRNA. While 
the amount of RNA structure in the MA region of gag 
is much lower than that of the 5′ UTR [32], we cannot 
exclude that the synonymous mutations in gag have not 
altered nearby structures. The known structures in the 
nucleotides that we have mutated are the IRES [29, 53, 
81, 82] and the region that base pairs with the 3′ end of 
the genome [33, 35]. In the context of single cycle infec-
tivity assays in HeLa cells (Fig. 4) and replication in MT4 
cells [60], neither the IRES nor circularization of the 
HIV-1 gRNA appear to be necessary because the region 
containing these elements can be deleted. However, it is 
possible that the phenotype for mutating an RNA struc-
ture may not be the same as deleting it [83] and these 
structures could be necessary under conditions not 
tested in this study, such as cellular stress or the innate 
immune response [6].
Two previous reports have shown that introduc-
ing synonymous mutations into gag or pol attenuates 
HIV-1 replication [54, 84]. Martrus et al. [84] introduced 
codon pairs into gag or pol that are underrepresented 
relative to human mRNAs, which strongly inhibited viral 
Fig. 9 Introduction of CpG dinucleotides into gag inhibits infectious virus production in HeLa cells. HeLa cells were transfected with pHIV‑1NL4‑3, 
pHIV‑1 CpG22‑165, pHIV‑1 CpG22‑261 or pHIV‑1 CpG22‑378. a Culture supernatants were used to infect TZM‑bl reporter cells to measure viral infec‑
tivity. The bar charts show the average values of four independent experiments normalized to the value obtained for HIV‑1NL4‑3. b Gag expression 
in the media and cell lysate was determined by quantitative immunoblotting. The bar charts show the average of three independent experiments 
normalized to HIV‑1NL4‑3. Error bars represent standard deviation. RNA was extracted from cell lysates and media (c, d) and gRNA abundance was 
quantified by qRT‑PCR. b–d The bar charts show the average of three independent experiments normalized to HIV‑1NL4‑3. Error bars represent stand‑
ard deviation
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replication. However, codon pair bias in RNA viruses has 
recently been shown to be due CpG and UpA dinucleo-
tide suppression and codon pair deoptimization increases 
CpG abundance [74, 85]. While not discussed in their 
study, the synonymous mutations that Martrus et  al. 
introduced increased the number of CpG dinucleotides 
in gag from 15 to 118. Therefore, we hypothesize that the 
decrease in viral replication observed in this study is at 
least partially a result of increasing the CpG frequency 
instead of codon pair deoptimization. To analyze the 
role of the A-rich RNA sequence for HIV-1 replication, 
Keating et al. [54] codon modified regions within gag and 
pol by increasing the number of C- and G-rich codons, 
which also inhibited HIV-1 replication. phGag-Pol [86] 
was used as the source of codon modified sequence and 
this has a large increase in CpG dinucleotide abundance 
compared with the wild type sequence. These addi-
tional CpG dinucleotides could be responsible for viral 
attenuation instead of altering the A-rich codon bias. 
Supporting this hypothesis, Klaver et  al. [87] used phy-
logeny-instructed mutagenesis to increase or decrease 
the A-rich codon bias in an ~ 500 nt region of pol. In this 
study, the CpG dinucleotide abundance was decreased 
by one in the A-Max mutant virus and only increased by 
four in the A-Min mutant virus. Substantially increasing 
or decreasing the number of A nucleotides did not affect 
HIV-1 replication, demonstrating that it is important to 
avoid introducing suppressed dinucleotides such as CpG 
in mutagenesis studies analyzing the functional relevance 
of nucleotide or codon bias.
While CpG dinucleotides appear to be under negative 
selection in HIV-1 [36, 40, 44, 55–57], the specific selec-
tion pressure has been unclear. There are at least four 
potential causes for the suppressed abundance of CpG 
dinucleotides in HIV-1. First, this could be due to a muta-
tional bias caused by cytosines in a CpG context in the 
proviral DNA becoming methylated and then undergo-
ing rapid spontaneous deamination. However, we have 
shown that increasing the abundance of CpG dinucleo-
tides inhibits viral replication, even in a single round 
assay (Figs. 1, 2, 8, 9). Second, CpG methylation-induced 
transcriptional silencing could inhibit HIV-1 gene 
expression [36, 40, 44, 55–57, 88]. However, this cannot 
cause the inhibition in the single cycle infectivity assays 
because the transfected proviral plasmids were amplified 
in bacteria, which does not methylate CpG dinucleotides. 
Importantly, when an unmethylated plasmid is trans-
fected into mammalian cells, the CpG dinucleotides are 
not methylated [89–91]. Third, unmethylated CpGs in the 
DNA could be recognized by TLR9 [88, 92]. This pattern 
recognition receptor is expressed in plasmacytoid den-
dritic cells, macrophages, and B cells [75] and therefore 
is unlikely to be expressed in HeLa cells. We confirmed 
that HeLa cells do not induce STAT1 phosphorylation 
or IFIT1 expression in response to CpG DNA (Addi-
tional file 3). In addition, IFN-α does not inhibit wild type 
HIV-1 infectious virus production in HeLa cells at most 
concentrations (10–1000  U/ml) and only has moderate 
inhibition at very high concentrations (10,000 U/ml) [93]. 
Therefore, the inhibition that we observe in response to 
introducing CpG dinucleotides into HIV-1 is unlikely to 
be due to the production of type I interferon.
The fourth possibility is that CpG dinucleotides in 
the viral RNA could induce an antiviral response that 
restricts HIV-1 replication. The frequency of CpG 
dinucleotides is suppressed in many RNA viruses that 
do not have a DNA intermediate [57, 92, 94–96], indi-
cating that CpG DNA methylation or activation of 
TLR9 cannot be responsible for CpG suppression in 
all viruses. Introduction of CpG dinucleotides into 
picornaviruses or influenza A virus inhibits viral rep-
lication [71–74]. It is unclear how CpG dinucleotides 
restrict RNA virus replication but, for the picornavi-
rus echovirus 7, it is not due to stimulating the inter-
feron pathway, PKR, conventional pattern recognition 
receptors or altering the translation efficiency of viral 
proteins [71, 74]. It has been hypothesized that there is 
an innate immune sensor that detects CpG dinucleo-
tides in viral RNA and leads to the inhibition of viral 
replication, though the molecular details are unknown 
[71, 73, 74, 85, 92, 97–99]. We favor the hypothesis 
that the proposed active restriction pathway targeting 
CpG dinucleotides in RNA viruses inhibits HIV-1 with 
an increased CpG abundance. When 26 CpG dinu-
cleotides were added within nt 22-378 of gag (HIV-1 
CpG22-378), which is  <  5% of the HIV-1 gRNA, viral 
replication was inhibited in Jurkat cells (Fig.  8) and 
infectivity was decreased by  ~  99% in a single round 
assay (Fig. 9). This indicates that the CpG dinucleotides 
induce a potent restriction.
While this manuscript was under review, Takata et al. 
[100] reported that introducing CpG dinucleotides 
into env inhibited HIV-1 replication by decreasing the 
abundance of cytoplasmic gRNA, Gag expression, Env 
expression and infectious virus production. They also 
demonstrated that depleting the cellular RNA binding 
protein ZAP rescues replication of HIV-1 with increased 
CpG abundance and ZAP directly binds HIV-1 RNA 
regions containing CpG dinucleotides. This indicates that 
ZAP restricts replication of HIV-1 containing increased 
CpG abundance, though it is unclear how ZAP promotes 
viral RNA degradation. Interestingly, we and others have 
shown that Gag is efficiently expressed from mammalian 
expression vectors that encode codon-optimized gag or 
gag-pol cDNAs containing large numbers of CpG dinu-
cleotides [61, 68, 86, 101, 102]. Therefore, it appears that 
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CpG dinucleotides in the context of full length HIV-1 is 
more deleterious for protein expression than CpGs in the 
context of mammalian expression vectors. How the spe-
cific context of CpG dinucleotides affects ZAP binding to 
RNA or modulates its activity will be an exciting area of 
future research.
Conclusions
The HIV-1 RNA sequence contains specific nucleotide 
features such as a low abundance of CpG dinucleotides. 
Our data shows that introducing CpG dinucleotides into 
HIV-1 inhibits viral replication by affecting multiple 
steps of the life cycle. This provides a functional explana-
tion for why CpG dinucleotides are suppressed in HIV-1 
and we speculate this dinucleotide is under negative 
selection to avoid an active restriction system that may 
require ZAP. Understanding how this restriction system 
inhibits replication of HIV-1 with increased CpG abun-
dance may provide insight into how other RNA viruses, 
such as picornaviruses and influenza A virus, are attenu-
ated when CpG dinucleotides are introduced.
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